Habano et al. BMC Cancer 2011, 11:81 http://www.biomedcentral.com/1471-2407/11/81 4. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54:1271-1294. 5. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT: Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004, 75:172-183. 6. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS: Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999, 27:804-809. 7. Turan N, Katari S, Coutifaris C, Sapienza C: Explaining inter-individual variability in phenotype: Is epigenetics up to the challenge? Epigenetics 2010, 5:16-19. 8. Demura M, Bulun SE: CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activityMol Cell. Endocrinol 2008, 283:127-132. 9. Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F, Ohki M, Imoto I, Inazawa J: Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 2005, 65:10233-10242. 10. Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G, Ozawa S: CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol 2009, 34:1085-1091. 11. Habano W, Sugai T, Nakamura S, Yoshida T: A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. Lab Invest 1996, 74:933-940. 12. CpG Island Searcher. [http://cpgislands.usc.edu/]. 13. Takai D, Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002, 99:3740-1833745. 14. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol 1987, 196:261-282. 15. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25:2532-2534. 16. Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, Evans DC: Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics 2006, 16:579-599. 17. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J, Schuetz E: Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001, 60:1399-1406. 18. Aouabdi S, Gibson G, Plant N: Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 2006, 34:138-144. 19. Kurose K, Ikeda S, Koyano S, Tohkin M, Hasegawa R, Sawada J: Identification of regulatory sites in the human PXR (NR1I2) promoter region. Mol Cell Biochem 2006, 281:35-43. 20. Kurose K, Koyano S, Ikeda S, Tohkin M, Hasegawa R, Sawada J: 5’ diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol Cell Biochem 2005, 273:79-85. 21. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature 1993, 361:657-660. 22. Xie Y, Ke S, Ouyang N, He J, Xie W, Bedford MT, Tian Y: Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem 2009, 284:9199-9205. 23. Kojima K, Nagata K, Matsubara T, Yamazoe Y: Broad but distinct role of pregnane X receptor on the expression of individual cytochrome P450 in human hepatocytes. Drug Metab Pharmacokinet 2007, 22:276-286. 24. Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, Hollande F, Lumbroso S, Brouillet JP, Evrard A: Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 2010, 9:46. 25. Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, Yao H, Zhou B, Tian Y: Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer 2010, 102:1753-1761. Page 10 of 10 26. Zhou J, Liu M, Zhai Y, Xie W: The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol 2008, 22:868-880. 27. Wheeler JM, Beck NE, Kim HC, Tomlinson IP, Mortensen NJ, Bodmer WF: Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: The predominant role of hMLH1. Proc Natl Acad Sci USA 1999, 96:10296-10301. 28. Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, Rognum TO, Esteller M, Lothe RA: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 2004, 3:28. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/81/prepub doi:10.1186/1471-2407-11-81 Cite this article as: Habano et al.: Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 2011 11:81. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit